Literature DB >> 23259420

Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.

William C S Cho, Dimitrios H Roukos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23259420     DOI： 10.1586/era.12.152

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  2 in total

Review 1.  Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Int J Mol Sci       Date:  2014-08-08       Impact factor: 5.923

2.  A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models.

Authors:  Wafaa Hassan; Kenny Chitcholtan; Peter Sykes; Ashley Garrill
Journal:  Oncol Ther       Date:  2016-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.